Table 2 HIV parameters at first AMI episode
SHCS | ||
|---|---|---|
HIV-positive subjects | ||
N Total | ||
Transmission risk category | 133 | |
Heterosexual intercourse | 42 (32) | |
Injection drug use | 20 (15) | |
Men-who-have-sex-with-men | 61 (46) | |
Other/unknown | 10 (7) | |
Time since HIV diagnosis (years) | 124 | 12 (8–18) |
Patients with viral load <40 copies per mL | 123 | 95 (77) |
CD4 cell count per mm3 | 129 | 462 (347–701) |
Antiretroviral treatment at the first episode of AMI | ||
Antiretroviral naïve | 133 | 1 (1) |
Not naïve, but not currently on antiretroviral drugs | 133 | 12 (7) |
On antiretroviral drugs | 133 | 120 (90) |
Antiretroviral regimen containing abacavir | 120 | 51 (43) |
Exposure to antiretroviral treatments (previous and current) | ||
Patients on PI (previous or current) | 132 | 113 (85.6) |
Median duration of PI therapy (years) | 113 | 5.6 (3.5–9.4) |
Patients under NNRTI (previous or current) | 132 | 88 (86) |
Median duration of NNRTI therapy (years) | 88 | 3.5 (0.6–5.9) |
Patients on NRTI (previous or current) | 132 | 126 (95) |
Median duration of NRTI therapy (years) | 126 | (6.7–15.1) |